FDA Approves Avelumab Plus Axitinib for Advanced RCC

On May 14, Pfizer Inc. announced that the FDA has approved avelumab (Bavencio) plus axitinib (Inlyta) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). A Phase III study showed that the combination significantly lowered risk of disease progression or death by 31 percent and extended progression-free survival by 5.4 months for patients with advanced RCC compared with sunitinib.

Read the Pfizer press release.

Posted 5/15/2019

Upcoming Events

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual Oncology Reimbursement Meeting (ORM) | Winter 2026

Virtual December 9, 2026 at 11:00 AM EST
2027 ACCC Leadership Summit

2027 ACCC Leadership Summit

In Person April 22, 2027 at 6:00 PM EDTWillard InterContinental Hotel, 1401 Pennsylvania Avenue Northwest, Washington, DC, USAWashington